Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudit

v3.21.2
Condensed Consolidated Statements of Operations (Unaudit - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Income Statement [Abstract]        
Revenue $ 512,500
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 385,002
Research and development expenses (including non-cash share-based compensation expenses of $1,687,754, $394,842, $2,425,136 and $1,250,497, respectively) 2,166,622 1,254,131 4,016,449 3,973,509
General and administrative expenses (including non-cash share-based compensation expenses of $1,499,572, $646,957, $2,799,561 and $1,922,722, respectively) 2,221,614 1,181,838 5,169,698 3,762,466
Total operating costs and expenses 4,388,236 2,435,969 9,571,149 7,735,975
Loss from operations (4,388,236) (2,435,969) (9,058,649) (7,735,975)
Other expense (148,084) (148,084)
Interest income 626 7,266 1,773 32,707
Net loss (4,387,610) (2,576,787) (9,056,876) (7,851,352)
Less: Net loss attributable to noncontrolling interest (53,621) (15,103) (115,745) (57,032)
Net loss attributable to common shareholders $ (4,333,989) $ (2,561,684) $ (8,941,131) $ (7,794,320)
Net loss per common share attributable to common shareholders: Basic and diluted $ (0.14) $ (0.11) $ (0.32) $ (0.36)
Weighted average common shares outstanding: Basic and diluted 30,455,340 23,165,066 28,090,163 21,678,608